Herceptin Treatment Time Could be Halved for Breast Cancer, Phase 3 Trial Finds
News
A shorter Herceptin (trastuzumab) treatment — six months instead of the standard 12 months — is equally effective and carries fewer heart-related adverse effects, a Phase 3 clinical trial found. The results ... Read more